This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

CVS Health will drop the weight-loss drug Zepbound from its insured pharmacy options this summer. Employers and insurers may ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Pharmaceutical company Eli Lilly announced promising clinical trial ... much like the extremely popular semaglutide-based injections, such as Novo Nordisk's Wegovy and Ozempic.